Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses  William H.D. Hallett, Erik Ames, Maite.

Slides:



Advertisements
Similar presentations
Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
Advertisements

Erik Ames, Salif Harouna, Colin Meyer, Lisbeth A. Welniak, William J
Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation  Michael Weber,
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells  Faith M. Young, Andrew.
Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease  Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,
IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy 
Role of Natural Killer Cells in Intravenous Immunoglobulin–Induced Graft-versus-Host Disease Inhibition in NOD/LtSz-scidIL2rg−/− (NSG) Mice  Joëlle Gregoire-Gauthier,
Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A
Krystel Vincent, Marie-Pierre Hardy, Assya Trofimov, Céline M
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine  Weiqing Jing,
Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation  Jian-ming Li, John Gorechlad,
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
Volume 15, Issue 2, Pages (February 2007)
by Norman Nausch, Ioanna E
Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.
Mycophenolic Acid Inhibits Natural Killer Cell Proliferation and Cytotoxic Function: A Possible Disadvantage of Including Mycophenolate Mofetil in the.
Volume 14, Issue 4, Pages (February 2016)
Human CD4+CD25+ Cells in Combination with CD34+ Cells and Thymoglobulin to Prevent Anti-hematopoietic Stem Cell T Cell Alloreactivity  Dolores Mahmud,
FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.
IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation  Lucrezia Colonna, Mareike.
Induction of Graft-versus-Leukemia (GVL) Effect without Graft-versus-Host Disease (GVHD) by Pretransplant Donor Treatment with Immunomodulators  Shoshana.
The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality  Kai Sun,
Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice  Chien-Chun Steven Pai,
Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.
Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.
Preventing Allograft Rejection by Targeting Immune Metabolism
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens  Hisaki Fujii,
Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses
Xinchun Chen, Yi Zeng, Gang Li, Nicolas Larmonier, Michael W
An Essential Role for IFN-γ in Regulation of Alloreactive CD8 T Cells Following Allogeneic Hematopoietic Cell Transplantation  Wannee Asavaroengchai,
Therapeutic Benefit of Bortezomib on Acute Graft-versus-Host Disease Is Tissue Specific and Is Associated with Interleukin-6 Levels  Chien-Chun Steven.
Volume 8, Issue 4, Pages (October 2003)
Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects  Lisbeth A. Welniak, Lynnette Shorts,
Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation  Isabel Barao, Maite.
Volume 13, Issue 1, Pages (January 2006)
Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine.
T Cell–Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model  Annie L. Oh, Dolores Mahmud, Benedetta Nicolini,
Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation  Jeffery J. Auletta,
Differential Expression of the Ly49GB6, but Not the Ly49GBALB, Receptor Isoform during Natural Killer Cell Reconstitution after Hematopoietic Stem Cell.
Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells 
T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.
The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.
Th2 Cell Therapy of Established Acute Graft-Versus-Host Disease Requires IL-4 and IL- 10 and Is Abrogated by IL-2 or Host-Type Antigen-Presenting Cells 
Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.
A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.
A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning  Gabor Varadi,
Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation 
Elevation of Intracellular Cyclic AMP in Alloreactive CD4+ T Cells Induces Alloantigen- Specific Tolerance That Can Prevent GVHD Lethality In Vivo  Matthew.
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.
Treatment with GM-CSF Secreting Myeloid Leukemia Cell Vaccine Prior to Autologous- BMT Improves the Survival of Leukemia-Challenged Mice  Jenny Zilberberg,
Recipient B Cells Are Not Required for Graft-Versus-Host Disease Induction  Catherine Matte-Martone, Xiajian Wang, Britt Anderson, Dhanpat Jain, Anthony.
Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.
CpG-Induced Myeloid CD11b+Gr-1+ Cells Efficiently Suppress T Cell–Mediated Immunoreactivity and Graft-Versus-Host Disease in a Murine Model of Allogeneic.
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects  Jeffrey S. Moyer, Gabriel.
Volume 17, Issue 2, Pages (February 2009)
Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:
Volume 25, Issue 1, Pages (January 2017)
Volume 24, Issue 1, Pages (January 2016)
Molecular Therapy - Oncolytics
Protective Regulatory T Cell Generation in Autoimmune Diabetes by DNA Covaccination with Islet Antigens and a Selective CTLA-4 Ligand  Yelena Glinka,
Volume 6, Issue 5, Pages (November 2002)
Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.
Volume 25, Issue 4, Pages (April 2017)
Fig. 2. In vivo local CD25-targeted NIR-PIT induces regression of treated LL/2-luc tumors. In vivo local CD25-targeted NIR-PIT induces regression of treated.
Presentation transcript:

Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses  William H.D. Hallett, Erik Ames, Maite Álvarez, Isabel Barao, Patricia A. Taylor, Bruce R. Blazar, William J. Murphy  Biology of Blood and Marrow Transplantation  Volume 14, Issue 10, Pages 1088-1099 (October 2008) DOI: 10.1016/j.bbmt.2008.08.001 Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 IL-2 promoted NK cell numbers, function, and antitumor effect in vivo. C57BL/6 mice were left untreated (control; ▪) or given IL-2 (2 × 1 05 IU on days 1, 3, 5, and 7 ▴). Spleens from the mice were removed on day 8, and the number of CD3-NK1.1+ NK cells were determined (n = 2) (A) and splenocytes from indicated treatment mice were used in a 4-hour chromium release assay against Yac-1 targets (n = 3) (B). Mice undergoing this treatment were challenged on day 0 with 2 × 105 C1498 cells i.v. and analyzed for survival (n = 8). ∗P < .05 as determined by the log-rank test (C). These data are representative of 5 experiments. Biology of Blood and Marrow Transplantation 2008 14, 1088-1099DOI: (10.1016/j.bbmt.2008.08.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 IL-2 increased Treg percentage and numbers. C57BL/6 mice were untreated or given IL-2, as described in Figure 1. The percentage of Foxp3+ cells out of total CD4+ cells is indicated for untreated mice (A) and IL-2–treated mice (B). The total CD4+Foxp3+ cells from control and IL-2–treated mice (n = 3) is also shown (C). These data are representative of 3 experiments. Biology of Blood and Marrow Transplantation 2008 14, 1088-1099DOI: (10.1016/j.bbmt.2008.08.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 CD25 was not expressed on resting or IL-2–activated NK cells in vivo. C57BL/6 mice were untreated or given IL-2, as described in Figure 1. Splenocytes were harvested on day 8, and CD25 and CD122 expression was determined on CD3-NK1.1+ cells from control mice (A) and IL-2–treated mice (B) (n = 3). These data are representative from 2 experiments. Biology of Blood and Marrow Transplantation 2008 14, 1088-1099DOI: (10.1016/j.bbmt.2008.08.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 IL-2 therapy increased Treg numbers, whereas anti-CD25 therapy reduced Treg numbers. A, Mice undergoing IL-2 therapy as in Figure 1 had spleens removed 1 day after treatment and splenocytes were analyzed for numbers of CD4+Foxp3+ cells (n = 3 mice per group). Analysis was by 1-way ANOVA with Dunnett's posttest. These data are representative of 5 experiments. B, Mice undergoing the same treatment as in (A), but with data given as the percentage of splenocytes that were CD4+ Foxp3+ (n = 2 or 3 mice per group). Analysis was by 1-way ANOVA with Bonferroni's posttest. The data are combined from 2 experiments. Biology of Blood and Marrow Transplantation 2008 14, 1088-1099DOI: (10.1016/j.bbmt.2008.08.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Increased NK cell numbers and activation by IL-2 were not enhanced by concurrent CD25 depletion. Mice undergoing IL-2 and anti-CD25 therapy had their spleens removed and analyzed for various parameters: total number of NK cells (A), histograms of control mice (B), IL-2 treated mice (C), anti-CD25 mice (D), and IL-2 and anti-CD25 mice (E), and MFI (F) of GzmB expression in CD3-NK1+ cells (n = 3). Analysis for (A) and (F) was by oneway ANOVA with Dunnett's posttest. These data are representative of 2 experiments. Biology of Blood and Marrow Transplantation 2008 14, 1088-1099DOI: (10.1016/j.bbmt.2008.08.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 IL-2 and αCD25 promoted tumor inhibition in long-term but not in short-term assays. C57BL/6 mice were treated with PBS (control; ▪), rhIL-2 (2 × 105 IU, days 0, 2, 4, and 6; ▴), αCD25 (PC61.5.3, 1 mg, days 0, 3, and 6; ▾), or rhIL-2 and αCD25 (●) before being sacrificed. Their splenocytes were used in a chromium release assay (A) or a tumor outgrowth assay (B). C, Effector cells used in (B) were plated in the absence of tumor cells to determine the proliferation of the effector cells. D, Mice undergoing IL-2 and anti-CD25 therapy were untreated or were given anti-NK1.1 or anti-CD8 antibodies and compared in the outgrowth assay. E, Activated NK cells from wild-type or pfp-/- mice were used in the tumor outgrowth assay. ∗P < .01. Statistical analysis was performed using 2-way ANOVA with a Bonferroni multiple-comparison test. Biology of Blood and Marrow Transplantation 2008 14, 1088-1099DOI: (10.1016/j.bbmt.2008.08.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 7 IL-2 therapy combined with CD25 depletion resulted in significant increase in survival compared with IL-2 alone. Mice were injected with 2 ×105 C1498 cells i.v. on day 0. The mice were injected with PBS/rIgG controls, with IL-2 (2 ×105 IU on days 1, 3, 5, and 7), with anti-CD25 antibodies (1 mg on days 1, 4, and 7), with IL-2 and anti-CD25 as above, or with IL-2 and anti-CD25 combined with anti-NK1.1 (500 μg on days 1 and 5). n = 8 mice per group. ∗P < .05 compared with rIgG/PBS. ∗∗P < .01 compared with either rIgG/PBS or IL-2 alone. These data are combined from 2 experiments. Biology of Blood and Marrow Transplantation 2008 14, 1088-1099DOI: (10.1016/j.bbmt.2008.08.001) Copyright © 2008 American Society for Blood and Marrow Transplantation Terms and Conditions